Pharmaceuticals, Biotechnology and Life Sciences
LAGUNA HILLS, Calif.–(BUSINESS WIRE)–#INDstatus–PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes…
Dupixent in patients 12 years and older with eosinophilic esophagitis (EoE) trial met both of its co-primary endpoints.
Ipsen’s results reveal the need for longer-lasting symptoms control to improve patients’ perceived quality of life
Tricida estimates that the net proceeds from the offering will be approximately $193.0 million
Takeda’s Alunbrig long-Term results from the phase 3 ALTA 1L trial established Alunbrig as a superior first-line treatment compared to crizotinib for people with ALK+ metastatic NSCLC, including those with brain metastases.
WOODCLIFF LAKE, N.J.–(BUSINESS WIRE)–Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle”) announced today that, due to public health and safety concerns related…
Advantech Capital and Vivo Capital have invested $15 million in Sinovac Research and Development Co., Ltd. (“Sinovac R&D”), a wholly owned subsidiary of Sinovac, to further the development of an inactivated vaccine against COVID-19 named CoronaVac.
AstraZeneca has concluded the first agreements for at least 400 million doses and has secured total manufacturing capacity for one billion doses so far and will begin first deliveries in September 2020.
$1.88 million in biomedical research grant funding for 2020 Class DENVER–(BUSINESS WIRE)–#cobioscience–The Boettcher Foundation has selected eight researchers to receive…
Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has been granted Orphan Drug Designation (ODD) in the US for the treatment of patients with gastric cancer, including gastroesophageal junction cancer.